Details

Autor(en) / Beteiligte

• Yamagami, Wataru
• Mikami, Mikio
• Nagase, Satoru
• Tabata, Tsutomu
• Kobayashi, Yoichi
• Kaneuchi, Masanori
• Kobayashi, Hiroaki
• Yamada, Hidekazu
• Hasegawa, Kiyoshi
• Fujiwara, Hiroyuki
• Katabuchi, Hidetaka
• Aoki, Daisuke

Titel

Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms

Ist Teil von

• Journal of Gynecologic Oncology, 2020, 31(1), , pp.1-21

Ort / Verlag

Korea (South): Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology

Erscheinungsjahr

2020

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The Fourth Edition of the Guidelines for Treatment of Uterine Body Neoplasm was published in 2018. These guidelines include 9 chapters: 1. Overview of the guidelines, 2. Initial treatment for endometrial cancer, 3. Postoperative adjuvant therapy for endometrial cancer, 4. Post-treatment surveillance for endometrial cancer, 5. Treatment for advanced or recurrent endometrial cancer, 6. Fertility-sparing therapy, 7. Treatment of uterine carcinosarcoma and uterine sarcoma, 8. Treatment of trophoblastic disease, 9. Document collection; and nine algorithms: 1-3. Initial treatment of endometrial cancer, 4. Postoperative adjuvant treatment for endometrial cancer, 5. Treatment of recurrent endometrial cancer, 6. Fertility-sparing therapy, 7. Treatment for uterine carcinosarcoma, 8. Treatment for uterine sarcoma, 9. Treatment for choriocarcinoma. Each chapter includes overviews and clinical questions, and recommendations, objectives, explanation, and references are provided for each clinical question. This revision has no major changes compared to the 3rd edition, but does have some differences: 1) an explanation of the recommendation decision process and conflict of interest considerations have been added in the overview, 2) nurses, pharmacists and patients participated in creation of the guidelines, in addition to physicians, 3) the approach to evidence collection is listed at the end of the guidelines, and 4) for clinical questions that lack evidence or clinical validation, the opinion of the Guidelines Committee is given as a "Recommendations for tomorrow".